Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

We recently published a list of 9 Stocks Jim Cramer Talked About. In this article, we are going to take a look at where ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

But it’s a slippery slope. When does reducing the risk of inherited breast cancer, diabetes, or Alzheimer’s disease edge into “designer baby” territory? As scientists grapple with the implications of ...

Scientists transformed energy-storing white fat cells into calorie-burning 'beige' fat. Once implanted, they outcompeted tumors for resources, beating back five different types of cancer in lab ...

Genesis announced that it has completed its second successful human transplant with a genetically engineered pig kidney, with ...

Furthermore, Crispr Therapeutics is expanding its studies in autoimmune disorders and Type 1 Diabetes, with anticipated updates that could diversify and strengthen its therapeutic portfolio.

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ ...